|
humans |
40 |
|
female |
37 |
|
male |
34 |
|
atrial fibrillation |
30 |
|
myocardial infarction |
27 |
|
aged |
24 |
|
stroke |
24 |
|
heart failure |
23 |
|
secondary prevention |
23 |
|
middle aged |
22 |
|
covid-19 |
21 |
|
sars-cov-2 |
20 |
|
adult |
18 |
|
chinese |
18 |
|
risk factors |
18 |
|
mortality |
17 |
|
treatment outcome |
17 |
|
ischemic stroke |
16 |
|
retrospective studies |
16 |
|
follow-up studies |
15 |
|
complications |
14 |
|
coronavirus infection |
14 |
|
health outcomes |
14 |
|
medical sciences |
14 |
|
osteoporosis |
14 |
|
percutaneous coronary intervention |
14 |
|
stem cells |
14 |
|
warfarin |
14 |
|
animals |
13 |
|
type 2 diabetes mellitus |
13 |
|
25-hydroxyvitamin d |
12 |
|
cohort studies |
12 |
|
cross-sectional studies |
12 |
|
endothelial progenitor cells |
12 |
|
recurrence |
12 |
|
endothelial function |
11 |
|
time in therapeutic range |
11 |
|
bnt162b2 |
10 |
|
cardiomyocytes |
10 |
|
cell differentiation |
10 |
|
coronavac |
10 |
|
covid-19 vaccine |
10 |
|
embryonic stem cells |
10 |
|
flow cytometry |
10 |
|
gastrointestinal haemorrhage |
10 |
|
genetic polymorphism |
10 |
|
induced pluripotent stem cells |
10 |
|
major adverse cardiovascular events |
10 |
|
myocardium - metabolism |
10 |
|
self-controlled case series |
10 |
|
stem cells - physiology |
10 |
|
vascular endothelial growth factor a - metabolism |
10 |
|
vascular function |
10 |
|
vitamin d-binding protein |
10 |
|
adult cardiology |
9 |
|
atherosclerosis |
9 |
|
blood pressure |
9 |
|
cardiac differentiation |
9 |
|
cardiology |
9 |
|
cardiovascular diseases |
9 |
|
cell differentiation - drug effects |
9 |
|
cha2ds2-vasc |
9 |
|
chads2 |
9 |
|
coronary artery disease |
9 |
|
diabetes |
9 |
|
garlic |
9 |
|
hypertension |
9 |
|
intracranial hemorrhage |
9 |
|
mice |
9 |
|
myocarditis |
9 |
|
spinal cord stimulation |
9 |
|
4d flow |
8 |
|
aged, 80 and over |
8 |
|
blood pressure variability |
8 |
|
calcium - metabolism |
8 |
|
cardiomyopathy |
8 |
|
cardiovascular and cerebrovascular diseases |
8 |
|
cardiovascular magnetic resonance |
8 |
|
carotid intima-media thickness |
8 |
|
cell line |
8 |
|
cell movement - drug effects |
8 |
|
dabigatran |
8 |
|
direct flow |
8 |
|
embryonic stem cell |
8 |
|
embryonic stem cells - cytology - drug effects - transplantation |
8 |
|
embryonic stem cells - cytology - metabolism |
8 |
|
ferric compounds - adverse effects |
8 |
|
green fluorescent proteins - analysis - biosynthesis |
8 |
|
hfpef |
8 |
|
hong kong |
8 |
|
incidence |
8 |
|
international normalized ratio |
8 |
|
intracerebral hemorrhage |
8 |
|
intraventricular flow |
8 |
|
magnetic resonance imaging - methods |
8 |
|
myocytes, cardiac - cytology - drug effects |
8 |
|
nanoparticles - adverse effects |
8 |
|
residual volume |
8 |
|
staining and labeling - methods |
8 |
|
superparamagnetic iron oxide |
8 |
|
trs 2Ā°p |
8 |
|
vascular markers |
8 |
|
vascular markers of atherosclerosis |
8 |
|
venous thromboembolism |
8 |
|
anoxia - metabolism |
7 |
|
antigens, differentiation - biosynthesis |
7 |
|
antimutagenic agents - pharmacology |
7 |
|
antiplatelet medication |
7 |
|
arrhythmias, cardiac - etiology |
7 |
|
biology |
7 |
|
cells, cultured |
7 |
|
cha2ds2-vasc score |
7 |
|
chads2 score |
7 |
|
circulating endothelial progenitor cells |
7 |
|
cobalt - pharmacology |
7 |
|
coronary heart disease |
7 |
|
cytokines - biosynthesis |
7 |
|
diabetes mellitus |
7 |
|
dietary supplements |
7 |
|
electrocardiography |
7 |
|
embryonic stem cells - cytology |
7 |
|
embryonic stem cells - transplantation |
7 |
|
endothelial dysfunction |
7 |
|
heart - physiology |
7 |
|
hip fractures |
7 |
|
hip fractures - surgery |
7 |
|
homeostasis - drug effects |
7 |
|
hypoxia |
7 |
|
hypoxia inducible factor-1Ī± |
7 |
|
hypoxia-inducible factor 1, alpha subunit - biosynthesis |
7 |
|
intracranial hemorrhages |
7 |
|
ischaemic heart disease |
7 |
|
lacunar infarct |
7 |
|
models, biological |
7 |
|
myocardial injury |
7 |
|
myocardium - cytology - metabolism |
7 |
|
myocytes, cardiac - transplantation |
7 |
|
non-vitamin k oral anticoagulants |
7 |
|
organ specificity - drug effects |
7 |
|
peritoneal dialysis |
7 |
|
pleiotropic effects |
7 |
|
pr prolongation |
7 |
|
proarrhythmias |
7 |
|
prognosis |
7 |
|
questionnaires |
7 |
|
registries |
7 |
|
rna, messenger - metabolism |
7 |
|
sarcoplasmic reticulum function |
7 |
|
signal transduction |
7 |
|
statin therapy |
7 |
|
statins |
7 |
|
stem cell transplantation - adverse effects |
7 |
|
swine |
7 |
|
troponin t - biosynthesis |
7 |
|
up-regulation |
7 |
|
ventricular remodeling |
7 |
|
adverse cardiovascular events |
6 |
|
adverse cardiovascular outcomes |
6 |
|
age factors |
6 |
|
alzheimer's disease |
6 |
|
ankle brachial index |
6 |
|
antiplatelet agents |
6 |
|
apolipoprotein a-i - metabolism |
6 |
|
arterial stiffiness |
6 |
|
arterial stiffness |
6 |
|
asian |
6 |
|
aspirin - administration & dosage - adverse effects |
6 |
|
atrial fibrillation - complications |
6 |
|
atrioventricular block - complications - diagnosis - physiopathology |
6 |
|
blood flow velocity |
6 |
|
bone marrow cells |
6 |
|
brachial artery - physiopathology |
6 |
|
brachial artery - physiopathology - ultrasonography |
6 |
|
brain ischemia - epidemiology - etiology |
6 |
|
calcium handling |
6 |
|
calcium signaling |
6 |
|
carcinoma, hepatocellular - etiology |
6 |
|
cardiovascular continuum |
6 |
|
cardiovascular death |
6 |
|
cardiovascular diseases - blood - diet therapy - prevention & control |
6 |
|
cardiovascular diseases - etiology |
6 |
|
cardiovascular diseases - etiology - physiopathology |
6 |
|
cardiovascular event |
6 |
|
carotid artery diseases - epidemiology - ultrasonography |
6 |
|
case-control studies |
6 |
|
catheter ablation - methods |
6 |
|
chads2 and cha2ds2-vasc scores |
6 |
|
chronic disease |
6 |
|
clinical outcomes |
6 |
|
comorbidity |
6 |
|
confounding factors (epidemiology) |
6 |
|
coronary artery disease - diagnosis - epidemiology |
6 |
|
coronary artery disease - epidemiology - radiography |
6 |
|
deferiprone |
6 |
|
deficiency diseases - complications - physiopathology |
6 |
|
diet |
6 |
|
diet records |
6 |
|
dna, viral - analysis |
6 |
|
drug-eluting stents |
6 |
|
echocardiography |
6 |
|
elderly |
6 |
|
electric countershock |
6 |
|
endothelial cells - cytology - physiology |
6 |
|
endothelium, vascular - cytology - physiology |
6 |
|
endothelium, vascular - physiopathology |
6 |
|
energy intake |
6 |
|
epicardial patch |
6 |
|
exercise capacity |
6 |
|
friedreich ataxia |
6 |
|
friedreich's ataxia |
6 |
|
general diabetes |
6 |
|
glycaemia |
6 |
|
glycated hemoglobin a |
6 |
|
has-bled score |
6 |
|
hba1c variability |
6 |
|
heart rate |
6 |
|
hepatitis b surface antigens - blood - immunology |
6 |
|
hepatitis b virus - genetics - immunology |
6 |
|
hepatitis b, chronic - blood - complications - immunology - pathology - virology |
6 |
|
high sensitive troponin level |
6 |
|
high-sensitivity troponin i |
6 |
|
homeostasis |
6 |
|
human embryonic stem cells |
6 |
|
human induced pluripotent stem cells |
6 |
|
hyperthyroidism |
6 |
|
hyperthyroidism - complications |
6 |
|
hypoglycemia |
6 |
|
ich volume |
6 |
|
idebenone |
6 |
|
induced pluripotent stem cells - cytology |
6 |
|
intracranial hemorrhages - drug therapy - physiopathology - surgery |
6 |
|
intraventricular extension |
6 |
|
ischemic cardiomyopathy |
6 |
|
isoflavone |
6 |
|
liver - chemistry - pathology |
6 |
|
liver cirrhosis - etiology |
6 |
|
liver neoplasms - etiology |
6 |
|
mitral valve |
6 |
|
multidetector computed tomography |
6 |
|
myocardial infarction - pathology - physiopathology - surgery |
6 |
|
myocytes, cardiac - cytology/drug effects - metabolism |
6 |
|
neurological deterioration |
6 |
|
non-st elevated myocardial infarction |
6 |
|
nutrition |
6 |
|
nutrition assessment |
6 |
|
pathophysiological mechanism |
6 |
|
pericardium - pathology - physiopathology |
6 |
|
phytoestrogen |
6 |
|
phytoestrogens - administration & dosage |
6 |
|
platelet aggregation inhibitors - administration & dosage - adverse effects |
6 |
|
pluripotent stem cells - cytology |
6 |
|
postmenopause |
6 |
|
pr interval prolongation |
6 |
|
prevalence |
6 |
|
proportional hazards models |
6 |
|
prospective studies |
6 |
|
prosthesis implantation - methods |
6 |
|
psoriasis |
6 |
|
psoriasis - epidemiology |
6 |
|
recurrent stroke |
6 |
|
regression analysis |
6 |
|
risk |
6 |
|
risk prediction |
6 |
|
selenium - administration & dosage - deficiency |
6 |
|
selenium deficiency |
6 |
|
smoking |
6 |
|
st segment elevation myocardial infarction |
6 |
|
statin |
6 |
|
statin intolerance |
6 |
|
stroke/prevention |
6 |
|
swine, miniature |
6 |
|
time factors |
6 |
|
timi grading system |
6 |
|
trace elements - deficiency |
6 |
|
type 2 |
6 |
|
vascular diseases - etiology - physiopathology |
6 |
|
vascular dysfunction |
6 |
|
vascular resistance |
6 |
|
vasodilation |
6 |
|
ventricular dysfunction, left - physiopathology - surgery |
6 |
|
ventricular remodeling - physiology |
6 |
|
visit-to-visit blood pressure variability |
6 |
|
warfarin-associated ich |
6 |
|
ablation |
5 |
|
acute coronary syndrome |
5 |
|
adverse events |
5 |
|
amiodarone - adverse effects - analogs and derivatives |
5 |
|
antibiotic agent |
5 |
|
anticoagulant |
5 |
|
anticoagulant agent |
5 |
|
arrhythmia |
5 |
|
aspirin |
5 |
|
atrial fibrillation - pathology - therapy |
5 |
|
atrial fibrillation and stroke |
5 |
|
atrioventricular block |
5 |
|
autophagy |
5 |
|
bleeding |
5 |
|
bone marrow |
5 |
|
bone marrow transplantation - methods - physiology |
5 |
|
brugada syndrome |
5 |
|
cardiac magnetic resonance imaging |
5 |
|
cardiac pacing, artificial |
5 |
|
cardiovascular diseases - mortality |
5 |
|
cell count |
5 |
|
chemicals and cas registry numbers |
5 |
|
chronic kidney disease |
5 |
|
clinical pharmacology |
5 |
|
clopidogrel |
5 |
|
coronary angiography |
5 |
|
coronary intervention |
5 |
|
diabetes mellitus, type 2 - pathology - physiopathology |
5 |
|
dilated cardiomyopathy |
5 |
|
dronedarone |
5 |
|
drug utilization |
5 |
|
echocardiography, doppler |
5 |
|
electrical cardioversion |
5 |
|
electrical stimulation |
5 |
|
electronics |
5 |
|
electrophysiologic techniques, cardiac |
5 |
|
embryonic stem cells - cytology - drug effects - metabolism |
5 |
|
embryonic stem cells - drug effects - enzymology - physiology |
5 |
|
enalapril |
5 |
|
endothelial cells - cytology |
5 |
|
endothelial cells - pathology |
5 |
|
exercise |
5 |
|
exercise tolerance |
5 |
|
fatal outcome |
5 |
|
gastrointestinal bleeding |
5 |
|
genetic analysis |
5 |
|
genome - genetics |
5 |
|
global healthsales |
5 |
|
glycogen storage disease type iib |
5 |
|
hematopoietic stem cells - cytology |
5 |
|
hepatocellular carcinoma |
5 |
|
hong kong - epidemiology |
5 |
|
hospitals |
5 |
|
immunohistochemistry |
5 |
|
infection |
5 |
|
ischaemic myocardium |
5 |
|
ischaemic stroke |
5 |
|
lamin a/c |
5 |
|
leukocytes, mononuclear - physiology |
5 |
|
lipid-modifying agents |
5 |
|
lmna |
5 |
|
long qt syndrome |
5 |
|
low-density lipoprotein cholesterol |
5 |
|
lung diseases - chemically induced |
5 |
|
methylprednisolone |
5 |
|
mexiletine |
5 |
|
microspheres |
5 |
|
microwaves - therapeutic use |
5 |
|
monomorphic ventricular tachycardia |
5 |
|
mus |
5 |
|
myocardial ischemia - physiopathology |
5 |
|
myocardial revascularization - methods |
5 |
|
myocytes, cardiac - drug effects - enzymology - physiology |
5 |
|
neovascularization |
5 |
|
neovascularization, physiologic |
5 |
|
non-vitamin k antagonist oral anticoagulants |
5 |
|
nonāvitamin k antagonist oral anticoagulants |
5 |
|
outcomes |
5 |
|
pacemaker |
5 |
|
pacing |
5 |
|
paracrine communication |
5 |
|
pharmacoepidemiolgy |
5 |
|
pharmacoepidemiology |
5 |
|
polymorphic ventricular tachycardia |
5 |
|
quinidine |
5 |
|
readmission |
5 |
|
realālife |
5 |
|
research design |
5 |
|
rivaroxaban |
5 |
|
sacubitril/valsartan |
5 |
|
species index: animalia |
5 |
|
stem cells - pathology |
5 |
|
transient ischaemic attack |
5 |
|
tricuspid valve insufficiency |
5 |
|
triiodothyronine - pharmacology |
5 |
|
valvular heart disease |
5 |
|
ventricular fibrillation |
5 |
|
ventricular function, left |
5 |
|
vitamin d |
5 |
|
vitamin d deficiency - pathology |
5 |
|
x-linked vacuolar cardiomyopathy and myopathy |
5 |
|
2-hour ecg |
4 |
|
3-(4,5-dimethyl-thiazol-2-yl)-2,5-dephenyltetrazolium bromide |
4 |
|
absorb |
4 |
|
action potential |
4 |
|
action potentials - physiology |
4 |
|
adenoma - complications |
4 |
|
administration, oral |
4 |
|
amiodarone - adverse effects |
4 |
|
annonaceae |
4 |
|
anti-arrhythmia agents - adverse effects |
4 |
|
anticholesteremic agents |
4 |
|
antilymphocyte serum - therapeutic use |
4 |
|
antiplatelet drugs |
4 |
|
article |
4 |
|
atrial fibrillation - etiology - therapy |
4 |
|
atrial function - physiology |
4 |
|
atrial high rate |
4 |
|
atrioventricular block - physiopathology - therapy |
4 |
|
atrioventricular block - therapy |
4 |
|
automaticity |
4 |
|
azathioprine - therapeutic use |
4 |
|
bare-metal stents |
4 |
|
bioartificial pacemaker |
4 |
|
biological clocks - physiology |
4 |
|
body mass index |
4 |
|
body temperature |
4 |
|
bone marrow cells - pathology |
4 |
|
brachial artery - pathology |
4 |
|
bradycardia |
4 |
|
bromodeoxyuridine |
4 |
|
cadaver |
4 |
|
cardiac pacing, artificial - adverse effects - methods |
4 |
|
cardiac pacing, artificial - methods |
4 |
|
cardiotonic agents - pharmacology |
4 |
|
cardiovascular diseases/prevention and control |
4 |
|
cerebellar hemorrhages |
4 |
|
china |
4 |
|
cholesterol, ldl |
4 |
|
clinical characteristics |
4 |
|
clinical pathway |
4 |
|
co-enzyme q10 |
4 |
|
coagulation |
4 |
|
colorectal neoplasms - complications |
4 |
|
community-acquired infections - epidemiology - microbiology |
4 |
|
congestive heart failure |
4 |
|
coronary artery disease - complications |
4 |
|
coronary artery disease - physiopathology |
4 |
|
coronary artery disease - physiopathology - rehabilitation |
4 |
|
coronary artery disease - ultrasonography |
4 |
|
creatinine - blood |
4 |
|
critical pathways - organization and administration |
4 |
|
crt |
4 |
|
cryptogenic |
4 |
|
cyclic nucleotide-gated cation channels - drug effects |
4 |
|
cyclic nucleotide-gated cation channels - genetics |
4 |
|
cyclosporine - therapeutic use |
4 |
|
cytomegalovirus infections - epidemiology |
4 |
|
dcm-associated mutations |
4 |
|
deep vein thrombosis |
4 |
|
diabetes mellitus - physiopathology |
4 |
|
diastole |
4 |
|
dinoprost - analogs & derivatives - blood |
4 |
|
disease association |
4 |
|
doppler echocardiography |
4 |
|
dosing |
4 |
|
double-blind method |
4 |
|
drug therapy, combination |
4 |
|
end-stage renal disease |
4 |
|
endocarditis, bacterial - epidemiology - microbiology |
4 |
|
endocarditis, bacterial - microbiology |
4 |
|
endothelial cells |
4 |
|
endothelial cells - physiology |
4 |
|
endothelial progenitor cell |
4 |
|
endothelial regeneration |
4 |
|
endothelin-1 |
4 |
|
endothelium cell |
4 |
|
endothelium, vascular - metabolism |
4 |
|
endothelium, vascular - physiology |
4 |
|
exercise - physiology |
4 |
|
experimental allergic encephalomyelitis |
4 |
|
extracellular matrix |
4 |
|
familial dilated cardiomyopathy |
4 |
|
familial hypercholesterolemia |
4 |
|
flow-mediated dilatation |
4 |
|
fluoroscopy |
4 |
|
gene expression - drug effects |
4 |
|
gene transfer |
4 |
|
genetic engineering - methods |
4 |
|
genomics |
4 |
|
geriatric hip fracture |
4 |
|
geriatric patients |
4 |
|
gram-positive bacterial infections |
4 |
|
hcn |
4 |
|
hcn channel |
4 |
|
health surveys |
4 |
|
heart atria - cytology - innervation |
4 |
|
heart conduction system - physiology |
4 |
|
heart diseases - complications - diagnosis |
4 |
|
heart failure - diagnosis - prevention & control |
4 |
|
heart failure - epidemiology - etiology - therapy |
4 |
|
heart failure - etiology |
4 |
|
heart right ventricle |
4 |
|
heart ventricles - cytology |
4 |
|
heart ventricles - cytology - innervation |
4 |
|
heart ventricles - ultrasonography |
4 |
|
hemodynamics - physiology |
4 |
|
human |
4 |
|
hypercholesterolemia |
4 |
|
hypercholesterolemia - physiopathology |
4 |
|
hypertension - ultrasonography |
4 |
|
hypertension, pulmonary - diagnosis - prevention & control |
4 |
|
hypertension, pulmonary - physiopathology |
4 |
|
hyperthyroidism - complications - epidemiology - physiopathology |
4 |
|
hyperuricaemia |
4 |
|
i f |
4 |
|
i k1 |
4 |
|
immunosuppressive agents - therapeutic use |
4 |
|
implantable cardioverter-defibrillater |
4 |
|
implanted pacemaker |
4 |
|
infective endocarditis |
4 |
|
infusions, intravenous |
4 |
|
initiation |
4 |
|
insertable cardiac monitor |
4 |
|
ion channel gating - physiology |
4 |
|
ipscs-derived cardiomyocyte-based disease model |
4 |
|
ipscs-derived cerebral cortical neurons |
4 |
|
ischemia |
4 |
|
kidney failure, chronic - physiopathology - therapy |
4 |
|
kidney transplantation - immunology - physiology |
4 |
|
lactococcus |
4 |
|
lamin a/c cardiomyopathy |
4 |
|
lamp2 deficiency |
4 |
|
leadless pacemaker |
4 |
|
left ventricular dyssynchrony |
4 |
|
length of stay - statistics and numerical data |
4 |
|
lesion |
4 |
|
lipids |
4 |
|
logistic models |
4 |
|
long-term outcome |
4 |
|
lung artery pressure |
4 |
|
lung vascular resistance |
4 |
|
lysosomal membrane permeabilization |
4 |
|
major clinical study |
4 |
|
manufacturers |
4 |
|
microwave |
4 |
|
mitochondrial function |
4 |
|
mitogen-activated protein kinase 1 - metabolism |
4 |
|
mitogen-activated protein kinase 3 - metabolism |
4 |
|
mitrephora monocarpa |
4 |
|
multidisciplinary |
4 |
|
multiple sclerosis |
4 |
|
multivariate analysis |
4 |
|
muscle, skeletal - pathology - physiology - surgery |
4 |
|
myoblasts, skeletal - pathology |
4 |
|
myocardial infarction - pathology - physiopathology - therapy |
4 |
|
myocardium - metabolism - pathology |
4 |
|
myocytes, cardiac - cytology - drug effects - metabolism |
4 |
|
myocytes, cardiac - cytology - physiology |
4 |
|
new species |
4 |
|
nitric oxide |
4 |
|
nitroglycerin - metabolism |
4 |
|
nitroglycerin-mediated dilatation |
4 |
|
nonsense mutation |
4 |
|
oral anticoagulant |
4 |
|
osteoporotic fractures - surgery |
4 |
|
ouabain |
4 |
|
ouabain - pharmacology |
4 |
|
oxidative stress-induced apoptosis |
4 |
|
oxygen consumption - physiology |
4 |
|
pacemaker, artificial |
4 |
|
pacemakers |
4 |
|
patch clamp |
4 |
|
patient care team - organization and administration |
4 |
|
patient-specific-induced pluripotent stem cells |
4 |
|
physical activity level |
4 |
|
physical endurance - physiology |
4 |
|
placebos |
4 |
|
postoperative complications - virology |
4 |
|
postoperative complications/prevention & control |
4 |
|
prednisolone - therapeutic use |
4 |
|
pregnancy |
4 |
|
premature atrial complexes |
4 |
|
preoperative care - methods |
4 |
|
prescribing |
4 |
|
primary prevention |
4 |
|
priority journal |
4 |
|
proinflammatory cytokines |
4 |
|
ptc124 |
4 |
|
pulmonary artery |
4 |
|
pulmonary artery - ultrasonography |
4 |
|
pulmonary artery systolic pressure |
4 |
|
pulmonary embolism |
4 |
|
pulmonary hypertension |
4 |
|
radiofrequency |
4 |
|
regenerative medicine |
4 |
|
regional wall motion abnormality |
4 |
|
rheumatic heart disease - epidemiology |
4 |
|
risk assessment |
4 |
|
ros |
4 |
|
safety |
4 |
|
septal pacing |
4 |
|
sleep apnea, central - diagnosis - prevention & control |
4 |
|
smoking - adverse effects |
4 |
|
staphylococcus aureus |
4 |
|
stem cell |
4 |
|
stem cell model |
4 |
|
stem cell transplantation |
4 |
|
strain rate |
4 |
|
substance abuse, intravenous - epidemiology |
4 |
|
sudden arrhythmic death |
4 |
|
sudden death |
4 |
|
superoxide dismutase - blood |
4 |
|
surgery |
4 |
|
surgical wound infection - prevention and control |
4 |
|
symptoms |
4 |
|
synergism |
4 |
|
systolic blood pressure |
4 |
|
t-wave alternans |
4 |
|
tachycardia, ventricular - diagnosis - epidemiology |
4 |
|
technique |
4 |
|
telemedicine |
4 |
|
th1 cells |
4 |
|
th17 cells |
4 |
|
thailand |
4 |
|
thyrotoxicosis - chemically induced |
4 |
|
tissue donors |
4 |
|
transgenic mice model |
4 |
|
translational read through |
4 |
|
transplantation, homologous |
4 |
|
trend |
4 |
|
ubiquinone - administration & dosage - analogs & derivatives - metabolism |
4 |
|
uric acid |
4 |
|
vascular smooth muscle cells |
4 |
|
ventricular dysfunction, left - diagnosis - epidemiology |
4 |
|
ventricular dysfunction, left - epidemiology - etiology - physiopathology - ultrasonography |
4 |
|
ventricular dysfunction, left - epidemiology - etiology - therapy |
4 |
|
ventricular dysfunction, left - pathology |
4 |
|
ventricular dyssynchrony |
4 |
|
ventricular function, left - drug effects |
4 |
|
ventricular function, left - physiology |
4 |
|
ventricular function, right - physiology |
4 |
|
ventricular tachycardia, ventricular fibrillation |
4 |
|
*life style |
3 |
|
*motor activity |
3 |
|
18f-fdg positron emission tomography |
3 |
|
acute myocardial infarction |
3 |
|
adenovirus |
3 |
|
adipocytes - cytology |
3 |
|
algorithms |
3 |
|
alpha-fetoproteins - analysis |
3 |
|
amino acid sequence |
3 |
|
amiodarone |
3 |
|
amiodarone - therapeutic use |
3 |
|
angiocardiography |
3 |
|
angioplasty, balloon, coronary - adverse effects - instrumentation - mortality |
3 |
|
angioplasty, balloon, coronary - adverse effects - mortality |
3 |
|
anti-arrhythmia agents - therapeutic use |
3 |
|
anticoagulants - adverse effects |
3 |
|
anticoagulation |
3 |
|
antineoplastic agents - therapeutic use |
3 |
|
antithyroid agents - therapeutic use |
3 |
|
aortic valve |
3 |
|
apixaban |
3 |
|
apob gene |
3 |
|
appendage pacing atrial dyssynchrony |
3 |
|
arrhythmia, sinus - diagnosis - epidemiology |
3 |
|
arrhythmias, cardiac - physiopathology - surgery |
3 |
|
arsenicals - administration & dosage - blood - therapeutic use |
3 |
|
asia |
3 |
|
asian continental ancestry group - statistics and numerical data |
3 |
|
atrial appendage - physiopathology - ultrasonography |
3 |
|
atrial contraction velocity |
3 |
|
atrial fibrillation - complications - drug therapy - physiopathology |
3 |
|
atrial fibrillation - diagnosis - epidemiology |
3 |
|
atrial fibrillation - physiopathology - therapy - ultrasonography |
3 |
|
atrial fibrillation - surgery |
3 |
|
atrial flutter - surgery |
3 |
|
atrial septum - physiopathology - ultrasonography |
3 |
|
atrial septum pacing |
3 |
|
atypical werner syndrome |
3 |
|
bacterial |
3 |
|
bifurcation lesions |
3 |
|
bioartificial organs |
3 |
|
blood coagulation disorders - chemically induced - drug therapy |
3 |
|
blood component transfusion |
3 |
|
blood glucose/metabolism |
3 |
|
blood pressure - physiology |
3 |
|
bone marrow-derived cells |
3 |
|
bundle-branch block - physiopathology - therapy |
3 |
|
cadmium - pharmacology |
3 |
|
calcium channels, l-type - metabolism |
3 |
|
calcium transients |
3 |
|
carbimazole - therapeutic use |
3 |
|
carcinoma, hepatocellular - drug therapy - secondary - surgery |
3 |
|
cardiac death |
3 |
|
cardiac output - physiology |
3 |
|
cardiac pacing, artificial - adverse effects - methods - trends |
3 |
|
cardiac progenitor cells |
3 |
|
cardiac rehabilitation |
3 |
|
cardiomegaly - complications - radiography - radionuclide imaging |
3 |
|
cardiomyopathy, dilated - genetics |
3 |
|
cardiovascular |
3 |
|
cardiovascular disease modeling |
3 |
|
cardiovascular diseases - etiology - mortality |
3 |
|
cascade screening |
3 |
|
catheter ablation |
3 |
|
caveolin 3 - metabolism |
3 |
|
china - epidemiology |
3 |
|
chronotropic incompetence |
3 |
|
coagulants - administration & dosage |
3 |
|
connecxin 43 |
3 |
|
coronary artery disease - complications - mortality - therapy |
3 |
|
coronary artery disease - drug therapy - physiopathology |
3 |
|
coronary artery disease - ethnology - mortality - radiography - therapy |
3 |
|
coronary artery disease/*blood/drug therapy/pathology/physiopathology |
3 |
|
cryosurgery - methods |
3 |
|
cyclic nucleotide-gated cation channels |
3 |
|
cyclic nucleotide-gated cation channels - chemistry - drug effects - genetics - metabolism |
3 |
|
cysteine - chemistry - genetics |
3 |
|
cysteine mutagenesis |
3 |
|
defibrillators, implantable - statistics and numerical data |
3 |
|
dementia |
3 |
|
device related thrombus |
3 |
|
diabetes mellitus, type 2 - complications - mortality |
3 |
|
diagnostic errors |
3 |
|
digoxin |
3 |
|
digoxin - therapeutic use |
3 |
|
diltiazem |
3 |
|
diltiazem - therapeutic use |
3 |
|
disease models, animal |
3 |
|
dithiothreitol - pharmacology |
3 |
|
dose-response relationship, drug |
3 |
|
drug acquisition costs |
3 |
|
drug administration schedule |
3 |
|
drug toxicity |
3 |
|
drug-eluting stent |
3 |
|
ehealth/telemedicine/mobile health |
3 |
|
electric stimulation |
3 |
|
electrocardiography, ambulatory |
3 |
|
electrocardiography. |
3 |
|
electrodes, implanted - adverse effects |
3 |
|
electrophysiology |
3 |
|
elemedicine |
3 |
|
endocarditis |
3 |
|
endocarditis, bacterial - etiology - mortality - surgery |
3 |
|
endothelium, vascular - drug effects - physiopathology |
3 |
|
endothelium, vascular/*metabolism/pathology/physiopathology |
3 |
|
exercise therapy |
3 |
|
f-18 fluorodeoxyglucose fdg |
3 |
|
feasibility studies |
3 |
|
fibrinolytic agents - contraindications - therapeutic use |
3 |
|
fluorodeoxyglucose f18 - diagnostic use |
3 |
|
fragmented qrs |
3 |
|
gastric acid |
3 |
|
gastric cancer |
3 |
|
gene transfer techniques |
3 |
|
genes |
3 |
|
genetic spectrum |
3 |
|
glycated haemoglobin a |
3 |
|
gram-positive bacilli |
3 |
|
gram-positive bacterial infections - diagnosis |
3 |
|
guinea pigs |
3 |
|
heart conduction system - drug effects - physiopathology |
3 |
|
heart conduction system - physiopathology |
3 |
|
heart failure - etiology - physiopathology |
3 |
|
heart failure - etiology - physiopathology - therapy |
3 |
|
heart rate - drug effects |
3 |
|
heart rate - physiology |
3 |
|
heart rate recovery |
3 |
|
heart valve diseases - surgery |
3 |
|
heart valve prosthesis |
3 |
|
heart valve prosthesis - adverse effects |
3 |
|
heart valve prosthesis implantation |
3 |
|
heart valve prosthesis implantation - adverse effects - instrumentation |
3 |
|
hemodynamics |
3 |
|
hemorrhagic stroke/transformation |
3 |
|
hepatectomy |
3 |
|
hindlimb - blood supply |
3 |
|
hospital mortality |
3 |
|
human induced pluripotent stem cell (hipsc) |
3 |
|
hutchinson gilford progeria |
3 |
|
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects |
3 |
|
hyperpolarization-activated cyclic nucleotide |
3 |
|
hypertension, pulmonary - etiology - physiopathology - ultrasonography |
3 |
|
hyperthyroidism - complications - physiopathology - ultrasonography |
3 |
|
hypoglycaemia |
3 |
|
implantable cardioverter-defibrillator |
3 |
|
induced pluripotent stem cells - cytology - physiology |
3 |
|
infection controlt |
3 |
|
inter- or intraatrial synchronicity |
3 |
|
interferon-alpha - therapeutic use |
3 |
|
ion channel gating - drug effects - genetics |
3 |
|
ion channels |
3 |
|
ion channels - genetics |
3 |
|
ischemia - chemically induced |
3 |
|
ischemia - surgery |
3 |
|
isosorbide dinitrate - administration & dosage - adverse effects - analogs & derivatives |
3 |
|
kaplan-meier estimate |
3 |
|
lactic acid/blood |
3 |
|
lamin type a - genetics |
3 |
|
ldlr gene |
3 |
|
left atrial appendage occlusion |
3 |
|
length of stay |
3 |
|
leukemia, promyelocytic, acute - diagnosis - drug therapy |
3 |
|
linear models |
3 |
|
lipids/blood |
3 |
|
liver neoplasms - drug therapy - pathology - surgery |
3 |
|
lung diseases - etiology - prevention and control |
3 |
|
lung metastasis |
3 |
|
lung neoplasms - drug therapy - secondary - surgery |
3 |
|
maces |
3 |
|
madit-ii trial |
3 |
|
mediastinum - radiography - radionuclide imaging |
3 |
|
mesenchymal stem cells |
3 |
|
mesenchymal stem cells - physiology |
3 |
|
metals |
3 |
|
microlife |
3 |
|
mitochondria, heart - drug effects - metabolism |
3 |
|
mitochondria/*metabolism/pathology |
3 |
|
mitochondrial diseases - chemically induced - metabolism |
3 |
|
mitochondrial dysfunction |
3 |
|
mobile app |
3 |
|
mycobacterium fortuitum |
3 |
|
mycobacterium infections, nontuberculous - diagnosis - etiology |
3 |
|
myocardial contraction |
3 |
|
myocardial infarction - etiology |
3 |
|
myocardial infarction - mortality - physiopathology - rehabilitation |
3 |
|
myocardial infarction - mortality - prevention and control |
3 |
|
myocardial infarction - therapy |
3 |
|
myocardial ischemia |
3 |
|
myocytes, cardiac - cytology - metabolism |
3 |
|
nerve sprouting |
3 |
|
nerve tissue proteins - metabolism |
3 |
|
neurology |
3 |
|
nitrate |
3 |
|
nnt |
3 |
|
ocular complication |
3 |
|
outer pore |
3 |
|
oxides - administration & dosage - blood - therapeutic use |
3 |
|
pacemaker channels |
3 |
|
pacemaker, artificial - adverse effects |
3 |
|
paroxysmal atria fibrillation |
3 |
|
paroxysmal atrial fibrillation |
3 |
|
patient selection |
3 |
|
pericarditis |
3 |
|
pericarditis - complications - radiography - radionuclide imaging |
3 |
|
pericarditis - diagnosis - etiology |
3 |
|
perioperative care - methods |
3 |
|
peripheral vascular disease |
3 |
|
photoplethysmography |
3 |
|
plasma |
3 |
|
platelet aggregation inhibitors - contraindications - therapeutic use |
3 |
|
pluripotent stem cells - cytology - transplantation |
3 |
|
pneumonectomy |
3 |
|
positron emission tomography/computed tomography |
3 |
|
positron-emission tomography |
3 |
|
postoperative complications - prevention and control |
3 |
|
potassium channels |
3 |
|
potassium channels - chemistry - drug effects - genetics - metabolism |
3 |
|
predictive value of tests |
3 |
|
premature ventricular beats |
3 |
|
prevention |
3 |
|
progeria - genetics |
3 |
|
propylthiouracil - therapeutic use |
3 |
|
prosthesis design |
3 |
|
prosthesis-related infections |
3 |
|
prosthesis-related infections - etiology - mortality - surgery |
3 |
|
protein transport |
3 |
|
proton pump inhibition |
3 |
|
pulmonary veins - surgery |
3 |
|
pyruvic acid/blood |
3 |
|
quality of life |
3 |
|
quality-of-life |
3 |
|
recombinant proteins |
3 |
|
recovered |
3 |
|
renal transplantation |
3 |
|
renin-angiotensin-aldosterone system |
3 |
|
reoperation |
3 |
|
repair |
3 |
|
reprogramming |
3 |
|
restenosis |
3 |
|
retina |
3 |
|
retinal vessels - drug effects |
3 |
|
retroviral reprogramming |
3 |
|
right ventricular apex |
3 |
|
ryanodine receptor |
3 |
|
ryanodine receptor calcium release channel - metabolism |
3 |
|
sarcoidosis |
3 |
|
screening |
3 |
|
sepsis - etiology - mortality |
3 |
|
severity of illness index |
3 |
|
sex difference |
3 |
|
sick sinus syndrome - physiopathology - surgery |
3 |
|
sick sinus syndrome - physiopathology - ultrasonography |
3 |
|
sinoatrial node |
3 |
|
sinoatrial node - physiology |
3 |
|
sinus node disease |
3 |
|
skeletal myoblasts |
3 |
|
smartphone |
3 |
|
stem cell characterization |
3 |
|
strain |
3 |
|
stroke/systemic embolism |
3 |
|
sudden cardiac death |
3 |
|
sulfhydryl modification |
3 |
|
surgical |
3 |
|
sympathetic innervation |
3 |
|
systemic interferon |
3 |
|
tachycardia, ventricular - etiology - prevention & control |
3 |
|
tissue doppler imaging |
3 |
|
tissue engineering |
3 |
|
tomography, x-ray computed |
3 |
|
transplantation |
3 |
|
troponin |
3 |
|
urology and nephrology |
3 |
|
valves |
3 |
|
vascular resistance - physiology |
3 |
|
vasodilator agents - administration & dosage - adverse effects |
3 |
|
ventricular dysfunction, left - etiology - physiopathology |
3 |
|
ventricular dysfunction, left - mortality - prevention and control |
3 |
|
ventricular function, right |
3 |
|
ventricular rate control |
3 |
|
ventricular tachyarrhythmia |
3 |
|
virology |
3 |
|
vitamin k - administration & dosage |
3 |
|
warfarin - adverse effects |
3 |
|
*coronary angiography |
2 |
|
*drug-eluting stents |
2 |
|
acs/nstemi |
2 |
|
acute inferior myocardial infarction |
2 |
|
acute myocardial infarction/stemi |
2 |
|
adaptation, physiological |
2 |
|
adenocarcinoma - complications - pathology - secondary |
2 |
|
af |
2 |
|
aneurysm - etiology - radiography - ultrasonography |
2 |
|
aneurysm, dissecting - diagnosis - mortality - surgery |
2 |
|
angina |
2 |
|
angina pectoris - etiology - physiopathology - radionuclide imaging - therapy |
2 |
|
angioplasty, balloon, coronary |
2 |
|
angioplasty, balloon, coronary - adverse effects - instrumentation - methods |
2 |
|
anti-hypertensive therapy |
2 |
|
antiarrhythmic agents |
2 |
|
anticoagulants - therapeutic use |
2 |
|
antineoplastic agents, phytogenic - therapeutic use |
2 |
|
aorta |
2 |
|
aorta stenosis |
2 |
|
aorta valve |
2 |
|
aortic aneurysm - diagnosis - mortality - surgery |
2 |
|
aortic diseases - diagnosis - mortality - surgery |
2 |
|
arterial occlusive diseases - etiology - radiography |
2 |
|
artifacts |
2 |
|
asian continental ancestry group |
2 |
|
atherosclerosis - etiology - metabolism - therapy - ultrasonography |
2 |
|
atrial fibrillation - blood - drug therapy |
2 |
|
atrial fibrillation - complications - etiology - physiopathology |
2 |
|
atrial fibrillation - complications - surgery |
2 |
|
atrial fibrillation - drug therapy - pathology |
2 |
|
atrial fibrillation - epidemiology - etiology |
2 |
|
atrial fibrillation - epidemiology - pathology - therapy |
2 |
|
atrial fibrillation - ethnology - genetics - pathology - physiopathology |
2 |
|
atrial fibrillation - physiopathology - therapy |
2 |
|
atrial fibrillation - prevention & control |
2 |
|
atrial fibrillation - prevention and control - therapy |
2 |
|
atrial fibrillation - therapy |
2 |
|
atrial fibrillation. |
2 |
|
atrial function |
2 |
|
atrioventricular node - physiopathology |
2 |
|
atrioventricular node - surgery |
2 |
|
atrium |
2 |
|
autonomic nervous system - physiopathology |
2 |
|
bare-metal stent |
2 |
|
barriers |
2 |
|
bioengineering |
2 |
|
bioresorbable vascular scaffold |
2 |
|
bioresorbable vascular scaffold; |
2 |
|
biventricular pacing |
2 |
|
bradycardia/therapy |
2 |
|
bypass surgery |
2 |
|
calcium - analysis |
2 |
|
calcium -- physiological effect |
2 |
|
carcinoma - complications - radiography |
2 |
|
carcinoma, hepatocellular - complications - pathology |
2 |
|
cardiac output |
2 |
|
cardiac output, low - etiology - ultrasonography |
2 |
|
cardiac output, low - physiopathology - therapy |
2 |
|
cardiac pacing. |
2 |
|
cardiac resynchronization |
2 |
|
cardiac resynchronization therapy |
2 |
|
cardiac resynchronization therapy - adverse effects |
2 |
|
cardiac resynchronization therapy devices |
2 |
|
cardiotonic agents/*administration & dosage |
2 |
|
cardiovascular agents/*administration & dosage |
2 |
|
carrier state |
2 |
|
cha2ds2āvasc score |
2 |
|
chest pain |
2 |
|
chi-square distribution |
2 |
|
cholesterol |
2 |
|
cigarette smoking |
2 |
|
clinical article |
2 |
|
clinical effectiveness |
2 |
|
clinical trials |
2 |
|
colectomy - adverse effects - methods |
2 |
|
colon cancer |
2 |
|
colonic neoplasms - complications - pathology |
2 |
|
colonoscopy |
2 |
|
colorectal cancer |
2 |
|
colorectal cancer surgery |
2 |
|
colorectal neoplasms - diagnosis - epidemiology |
2 |
|
colorectal neoplasms - surgery |
2 |
|
constriction, pathologic - etiology - ultrasonography |
2 |
|
continental population groups - genetics |
2 |
|
contrast media - diagnostic use |
2 |
|
controlled study |
2 |
|
coronary artery bypass |
2 |
|
coronary artery bypass - adverse effects |
2 |
|
coronary artery disease - complications - physiopathology |
2 |
|
coronary artery disease - physiopathology - radiography |
2 |
|
coronary bifurcation |
2 |
|
coronary circulation |
2 |
|
coronary disease - radiography - therapy |
2 |
|
coronary occlusion - diagnosis |
2 |
|
coronary restenosis |
2 |
|
coronary restenosis - drug therapy - mortality - prevention & control |
2 |
|
coronary restenosis - etiology - prevention & control - radiography |
2 |
|
coronary restenosis/epidemiology |
2 |
|
coronary restenosis/etiology |
2 |
|
coronary stenosis - pathology - radiography - therapy |
2 |
|
coronary stenosis - radiography - therapy |
2 |
|
coronary stenosis/radiography/*therapy |
2 |
|
coronary stent |
2 |
|
coronary vessels - pathology |
2 |
|
cross-over studies |
2 |
|
cryoablation |
2 |
|
ct scan |
2 |
|
defibrillators, implantable |
2 |
|
defibrillators, implantable - adverse effects |
2 |
|
device |
2 |
|
device removal |
2 |
|
drug eluting stent |
2 |
|
drug tolerance - physiology |
2 |
|
echocardiography - instrumentation |
2 |
|
echocardiography - methods |
2 |
|
electric countershock - statistics and numerical data |
2 |
|
electrocardiography - methods |
2 |
|
electrodes |
2 |
|
electrodes, implanted |
2 |
|
electromagnetic fields |
2 |
|
electromagnetic fields - adverse effects |
2 |
|
electromagnetic interference |
2 |
|
embryonic stem cells - physiology - transplantation |
2 |
|
endocardium - anatomy & histology - radiography |
2 |
|
endothelium, vascular - physiopathology - ultrasonography |
2 |
|
endothelium-dependent vasodilation |
2 |
|
epidemiology |
2 |
|
equipment design |
2 |
|
equipment failure |
2 |
|
esophagus |
2 |
|
esophagus - anatomy & histology - radiography |
2 |
|
exercise test |
2 |
|
exercise tolerance - physiology |
2 |
|
fat pad |
2 |
|
fibrinolytic agents - administration and dosage - therapeutic use |
2 |
|
fibrosis |
2 |
|
filter no reflow |
2 |
|
filtering surgery |
2 |
|
follow up |
2 |
|
functional capacity |
2 |
|
genetic engineering |
2 |
|
graft occlusion, vascular - drug therapy - surgery - therapy |
2 |
|
graft occlusion, vascular - etiology - metabolism - therapy - ultrasonography |
2 |
|
graft occlusion, vascular - etiology - radiography - ultrasonography |
2 |
|
graft occlusion, vascular - radiography - therapy |
2 |
|
health care outcomes |
2 |
|
health status disparities |
2 |
|
heart atria - anatomy & histology - radiography |
2 |
|
heart atria - pathology |
2 |
|
heart cells |
2 |
|
heart disease |
2 |
|
heart diseases - therapy |
2 |
|
heart failure - drug therapy - etiology |
2 |
|
heart infarction |
2 |
|
heart ventricles |
2 |
|
heart ventricles - physiopathology - radionuclide imaging |
2 |
|
hematoma |
2 |
|
hematoma - diagnosis - mortality - surgery |
2 |
|
heparin |
2 |
|
heparin - administration and dosage - therapeutic use |
2 |
|
heparin, low-molecular-weight - administration and dosage - therapeutic use |
2 |
|
hepatitis b - complications |
2 |
|
hepatocytes |
2 |
|
herb-drug interactions - physiology |
2 |
|
herbs |
2 |
|
hernia, hiatal - complications |
2 |
|
high-density lipoproteins |
2 |
|
human liver chimeric mice |
2 |
|
hypertension - physiopathology |
2 |
|
hypertension, pulmonary - drug therapy - etiology |
2 |
|
hyperthyroidism - chemically induced - complications |
2 |
|
hypolipidemic agents - therapeutic use |
2 |
|
hypotension, orthostatic - physiopathology |
2 |
|
icd shock |
2 |
|
imaging, three-dimensional - methods |
2 |
|
incidental findings |
2 |
|
inferior wall myocardial infarction - diagnosis |
2 |
|
international normalized ratio - methods |
2 |
|
intravascular ultrasound |
2 |
|
ischemic heart disease |
2 |
|
ldl receptor |
2 |
|
lesion dimension |
2 |
|
leukocyte count |
2 |
|
leukocytosis - blood - diagnosis - epidemiology |
2 |
|
likelihood functions |
2 |
|
lipids - analysis |
2 |
|
liver cirrhosis - complications |
2 |
|
liver neoplasms - complications - secondary |
2 |
|
magnetic resonance angiography |
2 |
|
mass screening |
2 |
|
mediastinal neoplasms - complications - radiography |
2 |
|
medical therapy |
2 |
|
membrane potentials - physiology |
2 |
|
metabolic syndrome x |
2 |
|
monitoring, physiologic |
2 |
|
muscles - pathology |
2 |
|
myocardial infarction - blood - epidemiology |
2 |
|
myocardial infarction - complications - drug therapy - physiopathology |
2 |
|
myocardial infarction/epidemiology |
2 |
|
myocardial infarction/etiology |
2 |
|
myocardial perfusion imaging - methods |
2 |
|
myocardium - cytology |
2 |
|
myocytes, cardiac - physiology |
2 |
|
necrosis |
2 |
|
neoplasms, multiple primary |
2 |
|
nitrate tolerance |
2 |
|
nitrate-mediated dilatation |
2 |
|
nitroglycerin - pharmacology |
2 |
|
no-reflow phenomenon - etiology - radiography - therapy |
2 |
|
nonpharmacologic therapy |
2 |
|
oral anticoagulants |
2 |
|
orthostatic hypotension |
2 |
|
outcome and process assessment (health care) |
2 |
|
pacing algorithm |
2 |
|
paclitaxel - administration & dosage |
2 |
|
paclitaxel - therapeutic use |
2 |
|
pathogenesis |
2 |
|
pcsk9 antibodies |
2 |
|
percutaneous coronary intervention/adverse effects/*instrumentation |
2 |
|
physiology |
2 |
|
pilot projects |
2 |
|
plant preparations - blood - therapeutic use |
2 |
|
postoperative complications |
2 |
|
postoperative complications - etiology - therapy |
2 |
|
posture - physiology |
2 |
|
potassium channels - genetics - metabolism |
2 |
|
pulmonary edema - etiology - ultrasonography |
2 |
|
pulmonary embolism - complications - radiography |
2 |
|
race |
2 |
|
radial artery catheter |
2 |
|
radionuclide ventriculography - methods |
2 |
|
radiopharmaceuticals - diagnostic use |
2 |
|
recovery of function |
2 |
|
recurrence - prevention and control |
2 |
|
regional blood flow - physiology |
2 |
|
revascularization |
2 |
|
right heart failure |
2 |
|
right ventricular pacing site |
2 |
|
saphenous vein - chemistry - transplantation - ultrasonography |
2 |
|
saphenous vein - radiography - transplantation - ultrasonography |
2 |
|
saphenous vein - surgery - transplantation |
2 |
|
saphenous vein - transplantation |
2 |
|
saphenous vein graft |
2 |
|
saphenous vein graft intervention |
2 |
|
saphenous vien graft lesions |
2 |
|
scimitar syndrome - diagnosis - radiography |
2 |
|
scimitar syndrome - radiography |
2 |
|
sensitivity and specificity |
2 |
|
shock - etiology - physiopathology |
2 |
|
single-blind method |
2 |
|
sirolimus/administration & dosage/*analogs & derivatives |
2 |
|
sleeve technique |
2 |
|
stenting technique |
2 |
|
stents |
2 |
|
stroke - etiology - physiopathology - prevention & control |
2 |
|
stroke volume |
2 |
|
stroke volume - physiology |
2 |
|
supine position |
2 |
|
surgery, computer-assisted - methods |
2 |
|
survival |
2 |
|
survival analysis |
2 |
|
survival rate |
2 |
|
tachycardia, ventricular - complications - prevention & control |
2 |
|
tachycardia, ventricular - diagnosis - surgery |
2 |
|
thrombectomy - instrumentation - methods |
2 |
|
thromboembolism - etiology - therapy |
2 |
|
thrombus aspiration |
2 |
|
tomography, emission-computed, single-photon |
2 |
|
tomography, x-ray computed - instrumentation - methods |
2 |
|
transcutaneous electric nerve stimulation - adverse effects - methods |
2 |
|
transcutaneous electrical neuromuscle stimulation |
2 |
|
transducers |
2 |
|
treatment |
2 |
|
tubulin modulators - administration & dosage |
2 |
|
ultrasonography, interventional |
2 |
|
uscom |
2 |
|
user-computer interface |
2 |
|
vasodilation - drug effects - physiology |
2 |
|
vasodilator agents - pharmacology |
2 |
|
vasodilator agents - therapeutic use |
2 |
|
vein occlusion |
2 |
|
ventricular dysfunction, left - physiopathology |
2 |
|
ventricular dysfunction, left - physiopathology - therapy |
2 |
|
ventricular dysfunction, right - physiopathology |
2 |
|
ventricular function |
2 |
|
ventricular rate |
2 |
|
ventricular septum - physiology |
2 |
|
ventricular septum - physiopathology - radionuclide imaging |
2 |
|
virtual histology |
2 |
|
warfarin - blood - therapeutic use |
2 |
|
white blood cell count |
2 |
|
zotarolimus-eluting stent |
2 |
|
Ī²-blocker |
2 |
|
abnormalities, multiple |
1 |
|
acute coronary care |
1 |
|
acute inferoposterior myocardial infarction |
1 |
|
ambulatory electrocardiogram |
1 |
|
angina pectoris, variant - diagnosis - physiopathology - therapy |
1 |
|
angioplasty, transluminal, percutaneous coronary |
1 |
|
anomalous right coronary artery |
1 |
|
antagonist stroke |
1 |
|
aortic valve - abnormalities |
1 |
|
aortic valve - abnormalities - surgery - ultrasonography |
1 |
|
arterial occlusive diseases - complications - congenital - ultrasonography |
1 |
|
atrial fibrillation - mortality |
1 |
|
atrial infarction |
1 |
|
atrial premature complexes - mortality |
1 |
|
autocapture |
1 |
|
automation |
1 |
|
brachytherapy |
1 |
|
brachytherapy - adverse effects |
1 |
|
cardiac diagnostic/interventional catheterization |
1 |
|
cardiac free-wall rupture |
1 |
|
cardiac pacemakers. |
1 |
|
cardiac surgical procedures |
1 |
|
cardiology - methods |
1 |
|
cath-diagnostic cardiac catheterization |
1 |
|
chest pain - drug therapy - etiology |
1 |
|
clinical enzyme tests |
1 |
|
clos-closure vascular access |
1 |
|
coronary |
1 |
|
coronary artery disease - diagnosis - etiology |
1 |
|
coronary artery disease - mortality |
1 |
|
coronary artery disease - radiography - therapy |
1 |
|
coronary circulation - physiology |
1 |
|
coronary disease - diagnosis - etiology |
1 |
|
coronary disease - diagnosis - physiopathology |
1 |
|
coronary restenosis - etiology - mortality - radiotherapy |
1 |
|
coronary stenosis - radiotherapy - therapy |
1 |
|
coronary vasospasm - drug therapy - radiography |
1 |
|
coronary vessel anomalies - complications |
1 |
|
coronary vessel anomalies - complications - epidemiology - radiography |
1 |
|
creatine kinase - blood |
1 |
|
death, sudden, cardiac - epidemiology |
1 |
|
death, sudden, cardiac - etiology |
1 |
|
diagnosis, differential |
1 |
|
echocardiography, transesophageal |
1 |
|
electrocardiography - instrumentation |
1 |
|
endocardium - pathology |
1 |
|
equipment safety |
1 |
|
etiology |
1 |
|
femoral artery |
1 |
|
giant r wave |
1 |
|
heart atria - pathology - physiopathology |
1 |
|
heart atria - physiopathology |
1 |
|
heart conduction system - pathology - physiopathology |
1 |
|
heart diseases - complications |
1 |
|
heart failure - mortality |
1 |
|
heart injuries - pathology - surgery |
1 |
|
heart rupture - mortality - physiopathology |
1 |
|
heart septum - injuries - pathology - surgery |
1 |
|
heart ventricles - injuries - pathology |
1 |
|
heart ventricles - pathology - physiopathology |
1 |
|
hemostatic techniques - instrumentation |
1 |
|
hospitalization |
1 |
|
hypertension - complications |
1 |
|
hypoplastic left coronary cusp |
1 |
|
in-hospital mortality |
1 |
|
infarct-related lesion |
1 |
|
intraventricular conduction delay |
1 |
|
long term |
1 |
|
myocardial infarction - diagnosis - drug therapy |
1 |
|
myocardial infarction - diagnosis - physiopathology |
1 |
|
myocardial infarction - mortality - physiopathology |
1 |
|
myocardial infarction - physiopathology |
1 |
|
myocardial infarction - physiopathology - radiography |
1 |
|
myocardial ischemia - complications - diagnosis |
1 |
|
myocardial ischemia - etiology |
1 |
|
nitroglycerin - administration & dosage |
1 |
|
nongovernmental organization |
1 |
|
nonāvitamin k antagonist oral anticoagulants |
1 |
|
pacemaker, artificial - trends |
1 |
|
pci-percutaneous coronary intervention |
1 |
|
platelet aggregation inhibitors - therapeutic use |
1 |
|
pr-segment depression |
1 |
|
sick sinus syndrome - diagnosis - physiopathology |
1 |
|
smartphone electrocardiogram |
1 |
|
software |
1 |
|
takotsubo cardiomyopathy - diagnosis - physiopathology |
1 |
|
threshold management |
1 |
|
thrombosis - etiology |
1 |
|
variant angina |
1 |
|
vasodilator agents - administration & dosage |
1 |
|
vitamin k |
1 |
|
wounds, stab - pathology - surgery |
1 |
